Serum brain natriuretic peptide and C-reactive protein levels in adolescent with polycystic ovary syndrome

References

• Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–47.
   Google Scholar
• Chang R, Kazer R. Polycystic ovary syndrome. Glob. libr. women’s med. 2009; DOI 10.3843/GLOWM.10301.
   Google Scholar
• Sukalich S, Guzick D. Cardiovascular health in women with polycystic ovary syndrome. Semin Reprod Med 2003;21:309–315.
   PubMed Web of Science ®Google Scholar
• Dahlgren E, Janson PO, Johansson S, Lapidus L, Odén A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992;71:599–604.
   PubMed Web of Science ®Google Scholar
• Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321–328.
   PubMed Web of Science ®Google Scholar
• Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 2004;6:257–260.
   PubMed Web of Science ®Google Scholar
• Yu CM, Sanderson JE, Shum IO, Chan S, Yeung LY, Hung YT, Cockram CS, Woo KS. Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern. Eur Heart J 1996;17:1694–1702.
   PubMed Web of Science ®Google Scholar
• Birdsall MA, Farquhar CM, White HD. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 1997;126:32–35.
   PubMed Web of Science ®Google Scholar
• Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997;47:287–296.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419.
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.
   PubMed Web of Science ®Google Scholar
• Celik O, Sahin I, Celik N, Hascalik S, Keskin L, Ozcan H, Uckan A, Kosar F. Diagnostic potential of serum N-terminal pro-B-type brain natriuretic peptide level in detection of cardiac wall stress in women with polycystic ovary syndrome: a cross-sectional comparison study. Hum Reprod 2007;22:2992–2998.
   PubMed Web of Science ®Google Scholar
• Engin-Ustün Y, Ustün Y, Meydanli MM, Kafkasli A, Yetkin G. Are polycystic ovaries associated with cardiovascular disease risk as polycystic ovary syndrome? Gynecol Endocrinol 2006;22:324–328.
   PubMed Web of Science ®Google Scholar
• Toprak S, Yönem A, Cakir B, Güler S, Azal O, Ozata M, Corakçi A. Insulin resistance in nonobese patients with polycystic ovary syndrome. Horm Res 2001;55:65–70.
   PubMedGoogle Scholar
• DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005;83:1454–1460.
   PubMed Web of Science ®Google Scholar
• Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983;57:356–359.
   PubMed Web of Science ®Google Scholar
• Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 1987;65:499–507.
   PubMed Web of Science ®Google Scholar
• Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:1017–1023.
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Sancho J, San Millán JL. Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia 2003;46:625–633.
   PubMed Web of Science ®Google Scholar
• Barber TM, Golding SJ, Alvey C, Wass JA, Karpe F, Franks S, McCarthy MI. Global adiposity rather than abnormal regional fat distribution characterizes women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93:999–1004.
   PubMed Web of Science ®Google Scholar
• Venturoli S, Porcu E, Fabbri R, Pluchinotta V, Ruggeri S, Macrelli S, Paradisi R, Flamigni C. Longitudinal change of sonographic ovarian aspects and endocrine parameters in irregular cycles of adolescence. Pediatr Res 1995;38:974–980.
   PubMed Web of Science ®Google Scholar
• Appel SJ, Bannon JM. Hazardous waist: how body shape puts health at risk. Nurs Womens Health 2007;11:44–53.
   PubMedGoogle Scholar
• Yang L, Samarasinghe YP, Kane P, Amiel SA, Aylwin SJ. Visceral adiposity is closely correlated with neck circumference and represents a significant indicator of insulin resistance in WHO grade III obesity. Clin Endocrinol (Oxf) 2010;73:197–200.
   PubMed Web of Science ®Google Scholar
• Dixon JB, O’Brien PE. Neck circumference a good predictor of raised insulin and free androgen index in obese premenopausal women: changes with weight loss. Clin Endocrinol (Oxf) 2002;57:769–778.
   PubMed Web of Science ®Google Scholar